507 related articles for article (PubMed ID: 15781671)
1. Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy.
Querfeld C; Rosen ST; Kuzel TM; Kirby KA; Roenigk HH; Prinz BM; Guitart J
Arch Dermatol; 2005 Mar; 141(3):305-11. PubMed ID: 15781671
[TBL] [Abstract][Full Text] [Related]
2. Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis.
Kim YH; Jensen RA; Watanabe GL; Varghese A; Hoppe RT
Arch Dermatol; 1996 Nov; 132(11):1309-13. PubMed ID: 8915308
[TBL] [Abstract][Full Text] [Related]
3. Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma.
Duvic M; Apisarnthanarax N; Cohen DS; Smith TL; Ha CS; Kurzrock R
J Am Acad Dermatol; 2003 Jul; 49(1):35-49. PubMed ID: 12833006
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of narrowband UVB vs. PUVA in patients with early-stage mycosis fungoides.
Ponte P; Serrão V; Apetato M
J Eur Acad Dermatol Venereol; 2010 Jun; 24(6):716-21. PubMed ID: 19929938
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression.
Kim YH; Liu HL; Mraz-Gernhard S; Varghese A; Hoppe RT
Arch Dermatol; 2003 Jul; 139(7):857-66. PubMed ID: 12873880
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of 8-methoxypsoralen vs. 5-methoxypsoralen plus ultraviolet A therapy in patients with mycosis fungoides.
Wackernagel A; Hofer A; Legat F; Kerl H; Wolf P
Br J Dermatol; 2006 Mar; 154(3):519-23. PubMed ID: 16445785
[TBL] [Abstract][Full Text] [Related]
7. Folliculotropic mycosis fungoides: an aggressive variant of cutaneous T-cell lymphoma.
Gerami P; Rosen S; Kuzel T; Boone SL; Guitart J
Arch Dermatol; 2008 Jun; 144(6):738-46. PubMed ID: 18559762
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma.
Kannangara AP; Levitan D; Fleischer AB
J Dermatolog Treat; 2009; 20(3):169-76. PubMed ID: 19016373
[TBL] [Abstract][Full Text] [Related]
9. A chart review of patients with early stage mycosis fungoides treated with psoralen plus UVA (PUVA).
Soung J; Muigai W; Amin N; Stern DK; Lebwohl MG
J Drugs Dermatol; 2005; 4(3):290-4. PubMed ID: 15898283
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of blood eosinophilia in primary cutaneous T-cell lymphomas.
Tancrède-Bohin E; Ionescu MA; de La Salmonière P; Dupuy A; Rivet J; Rybojad M; Dubertret L; Bachelez H; Lebbé C; Morel P
Arch Dermatol; 2004 Sep; 140(9):1057-61. PubMed ID: 15381544
[TBL] [Abstract][Full Text] [Related]
11. Treatment of stage Ia and Ib mycosis fungoides with psoralen UVA monotherapy: an observational study in tertiary hospitals in the Canary Islands.
Hernández Z; Peñate Y; Hernández-Machín B; Pérez-Méndez L; Suárez-Hernández J; Hernández J; Fernández-de-Misa R
Int J Dermatol; 2014 Nov; 53(11):1417-22. PubMed ID: 24697305
[TBL] [Abstract][Full Text] [Related]
12. Narrowband UVB phototherapy for early-stage mycosis fungoides: evaluation of clinical and histopathological changes.
Gökdemir G; Barutcuoglu B; Sakiz D; Köşlü A
J Eur Acad Dermatol Venereol; 2006 Aug; 20(7):804-9. PubMed ID: 16898902
[TBL] [Abstract][Full Text] [Related]
13. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.
Olsen EA; Kim YH; Kuzel TM; Pacheco TR; Foss FM; Parker S; Frankel SR; Chen C; Ricker JL; Arduino JM; Duvic M
J Clin Oncol; 2007 Jul; 25(21):3109-15. PubMed ID: 17577020
[TBL] [Abstract][Full Text] [Related]
14. [Treatment results of stage IA Hodgkin lymphoma: a report of 97 cases].
Tan WY; Hu DS; Zeng FY; Song QB; Hu S; Wei L; Zhou LQ
Ai Zheng; 2007 Dec; 26(12):1360-4. PubMed ID: 18076802
[TBL] [Abstract][Full Text] [Related]
15. Ultimate results of radiation therapy for T1-T2 mycosis fungoides (including reirradiation).
Ysebaert L; Truc G; Dalac S; Lambert D; Petrella T; Barillot I; Naudy S; Horiot JC; Maingon P
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1128-34. PubMed ID: 15001254
[TBL] [Abstract][Full Text] [Related]
16. Extent of skin involvement as a prognostic indicator of disease free and overall survival of patients with T3 cutaneous T-cell lymphoma treated with total skin electron beam radiation therapy.
Quiros PA; Kacinski BM; Wilson LD
Cancer; 1996 May; 77(9):1912-7. PubMed ID: 8646693
[TBL] [Abstract][Full Text] [Related]
17. Psoralen plus ultraviolet A +/- interferon-alpha treatment resistance in mycosis fungoides: the role of tumour microenvironment, nuclear transcription factor-kappaB and T-cell receptor pathways.
Wozniak MB; Tracey L; Ortiz-Romero PL; Montes S; Alvarez M; Fraga J; Fernández Herrera J; Vidal S; Rodriguez-Peralto JL; Piris MA; Villuendas Deceased R
Br J Dermatol; 2009 Jan; 160(1):92-102. PubMed ID: 18945306
[TBL] [Abstract][Full Text] [Related]
18. Endoluminal resection for sessile neoplasia in the GI tract is associated with a low recurrence rate and a high 5-year survival rate.
Wang AY; Ahmad NA; Zaidman JS; Brensinger CM; Lewis JD; Long WB; Kochman ML; Ginsberg GG
Gastrointest Endosc; 2008 Jul; 68(1):160-9. PubMed ID: 18577483
[TBL] [Abstract][Full Text] [Related]
19. Narrowband UVB and PUVA in the treatment of mycosis fungoides: a retrospective study.
Ahmad K; Rogers S; McNicholas PD; Collins P
Acta Derm Venereol; 2007; 87(5):413-7. PubMed ID: 17721648
[TBL] [Abstract][Full Text] [Related]
20. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma.
Duvic M; Martin AG; Kim Y; Olsen E; Wood GS; Crowley CA; Yocum RC;
Arch Dermatol; 2001 May; 137(5):581-93. PubMed ID: 11346336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
